Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity

Circulation

Volumn 107, Issue 2, 2003, Pages 234-237

  Zhao, Lan ^a   Mason, Nicola A ^a   Strange, Julian W ^a   Walker, Hamish ^a   Wilkins, Martin R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Hypertension; Natriuretic peptides; Pulmonary; Remodeling

Indexed keywords

CYCLIC GMP; HORMONE RECEPTOR; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; PHOSPHODIESTERASE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; ISOLATED LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; TISSUE REPAIR;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ANOXIA; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CYCLIC GMP; DISEASE MODELS, ANIMAL; GUANYLATE CYCLASE; HOMOZYGOTE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MICE; MICE, MUTANT STRAINS; PERFUSION; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RESPIRATION, ARTIFICIAL; VENTRICULAR FUNCTION, RIGHT;

EID: 0037458096     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000050653.10758.6B     Document Type: Article

References (15)

1. Waldman SA, Murad F. Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system. J Cardiovasc Pharmacol. 1988;12:S115-S118.
2. Rybalkin SD, Bornfeldt KE. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemost. 1999;82:424-434.
3. Thomas MK, Francis SH, Corbin JD. Characterisation of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem. 1990;265:14964-14970.
4. Dukarm RC, Russell JA, Morin III FC, et al. The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation. Am J Respir Crit Care Med. 1999;160:858-865.
5. Hanasato N, Oka M, Muramatsu M, et al. E4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol. 1999;277:L225-L232.
6. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218-1222.
7. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxiainduced pulmonary hypertension. Circulation. 2001;104:424-428.
8. Michelakis E. Tymchal W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation. 2002;105:2398-2403.
9. Muramatsu M, Tyler RC. Gutkowska J, et al. Atrial natriuretic peptide accounts for increased cGMP in hypoxia-induced hypertensive rat lungs. Am J Physiol. 1997;272:L1126-L1132.
10. Lopez MJ, Wong SKF, Kishimoto I, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378:65-68.
11. Zhao L, Long L, Morrell NW, et al. NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation. 1999;99:605-607.
12. Klinger JR, Warburton RR, Pietras LA, et al. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. Am J Physiol. 2002;282:H58-H65.
13. Knowles JW, Esposito G. Mao L, et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide A-deficient mice. J Clin Invest. 2001;107:975-984.
14. Zhao L, Winter RJD, Krauz T, et al. Effects of continuous infusion of atrial natriuretic peptide on the pulmonary hypertension induced by chronic hypoxia in rats. Clin Sci. 1991;81:379-385.
15. Oliver PM, John SW, Purdy KE, et al. Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner. Proc Natl Acad Sci U S A. 1998;95:2547-2551.